April 20, 2021 -- Evotec will soon break ground on its first commercial biologics manufacturing facility in Europe at its Campus Curie in Toulouse, France.
Construction is expected to commence in the second half of this year on the facility, which will support the development and manufacturing of therapeutic antibodies for the treatment of infectious diseases, such as COVID-19, upon its planned completion in 2023, Evotec said.
The company's initial biologics manufacturing facility is nearing completion in Redmond, WA, and is scheduled to be fully operational in the second half of 2021.